Chemo-IO

Chemo-IO means:

Chemotherapy + Immunotherapy given together

In oncology practice, Chemo-IO specifically refers to cytotoxic chemotherapy combined with immuno-oncology (IO) agents, almost always immune checkpoint inhibitors.

What Each Part Does

Chemotherapy

• Directly kills rapidly dividing tumor cells
• Causes tumor antigen release
• Can reduce immunosuppressive cells in the tumor microenvironment

Immunotherapy (IO)

• Reactivates T-cells to recognize cancer
• Sustains long-term immune control
• Most commonly PD-1 / PD-L1 inhibitors

Together, chemo can make tumors more visible to the immune system, enhancing IO efficacy.

Common Chemo-IO Examples (High-Yield)

Non–Small Cell Lung Cancer (NSCLC)

• Carboplatin + pemetrexed + pembrolizumab
• Carboplatin + paclitaxel + pembrolizumab

Small Cell Lung Cancer (SCLC)

• Platinum + etoposide + atezolizumab
• Platinum + etoposide + durvalumab

Triple-Negative Breast Cancer

• Chemo + pembrolizumab (PD-L1+)

Head & Neck SCC

• Platinum + 5-FU + pembrolizumab

Biomarkers Often Used with Chemo-IO

• PD-L1 expression (not always required)
• Tumor mutational burden (TMB)
• MSI-H / dMMR (GI cancers)

Important: Chemo-IO can be used even if PD-L1 is low or negative, unlike IO alone.

Toxicity Considerations (Very Important for Pharmacy)

You get BOTH:

Key rule:

• Chemo toxicity → dose adjust
• IO toxicity → hold drug + corticosteroids

Links